Introduction
MicroRNAs (miRNAs) are small non-coding RNA molecules that are highly conserved throughout eukaryotic organisms. Before miRNAs become functionally active, they must undergo a series of post-transcriptional modifications. Mature single-stranded miRNAs downregulate gene translation, or mediate mRNA cleavage by utilizing partial sequence homology bind to targets in the 3′-untranslated region (3′-UTR) (1). Surprisingly, miRNAs also have the potential to suppress several target genes simultaneously (2). Similarly, numerous miRNAs play important roles as either oncogenes or tumor suppressor genes, and are involved in a variety of cellular processes including proliferation, apoptosis, tumorigenesis, and chemoresistance (3–5). Furthermore, several studies have shown that dysregulated miRNA expression is frequently found in various human cancers (6–9). More specifically, microRNA-203 (miR-203) has been found to regulate the suppressor of cytokine signaling 3 (SOCS3), which is involved in the negative-feedback regulation of JAK/STAT signal transduction (10). Additionally, there are some evidence that miR-203 is regulated by p53, while Nakano and Vousden (11) identified the novel gene Puma as a target for activation of p53. Currently, it is believed that Puma plays a role in p53-mediated apoptosis through the cytochrome-c/Apaf-1-dependent pathway (11). In the present study, we sought to investigate the tripartite relationship between miR-203, p53, and Puma in cancer cells (Fig. 1). We found that overexpressed miR-203 in HCT116 and A549 cells caused increased Puma expression and improved gemcitabine sensitivity. In addition, we found that activated p53 induced miR-203 and Puma expression, while downregulated p53 resulted in decreased expression levels of miR-203. These findings imply that miR-203 may have a variety of roles, including a tumor suppressor gene, a predictive marker of tumor response to chemotherapy, and therapeutic value as a potential target.
Materials and methods
Cell lines and culture conditions
Human colon cancer (HCT116) and lung cancer (A549) cell lines were cultured in Dulbecco's modified Eagle's medium (DMEM; Invitrogen, Carlsbad, CA, USA) with 10% fetal bovine serum (FBS), 100 μg/ml of streptomycin, and 100 U/ml of penicillin at 37°C in a humidified chamber supplemented with 5% CO2.
Oligonucleotides
Precursors of miR-203, its inhibitor, and its negative controls were purchased from Ambion (Tokyo, Japan). P53-shRNAs and their negative controls were purchased from Invitrogen (Tokyo, Japan).
Pre-miR-203 transfection experiments
miR-203, its inhibitor, and respective controls were transfected using RNAiMAX transfection reagent (Invitrogen). Transfection efficiency was determined using quantitative real-time polymerase chain reaction (PCR). A549 and HCT116 cells were transfected with 50 nM of miRNA in a 6-well plate for RNA extraction, or 10-cm dishes for further studies including proliferation, and gemcitabine sensitivity assays following the previously reported protocol (13). RNA was isolated 48 h after transfection to measure miR-203 and Puma expression. Cells from 10-cm dishes were transferred 12 h after transfection to 96-well plates for proliferation, drug sensitivity, and apoptosis assays, and 24-well plates for invasion assays. All transfection experiments were independently repeated three times.
RNA preparation and real-time PCR analysis
Total cellular RNA was extracted from cells cultured in 6-well plates using TRIzol (Invitrogen). Cell pellets were suspended in an aliquot of 1 ml/well according to the manufacturer's recommendations. Isolated RNA (6 μg) was combined with random primers (6-mer) for reverse transcription (GE Healthcare, Buckinghamshire, UK) following the manufacturer's instructions. Gene expression levels were measured using TaqMan real-time PCR (Applied Biosystems Life Technologies, Foster City, CA, USA) containing probes for 4 genes: Puma (ID: Hs00248075_m1), BAX (ID: Hs00180269_m1, TP53 (ID: Hs00153349_m1), and miR-203 (ID: 000507), with GAPDH (ID: Hs99999905_m1) and RNAU6 (ID: 001002) as internal controls for genes and miRs, respectively. Gene expression levels were calculated using the relative quantification ΔΔCt method as we reported previously (13). Each sample was assayed in triplicates.
Western blot analysis
In order to evaluate whether miR-203 affected Puma expression at the protein level, a western blot analysis was performed as previously reported (14). At 24 h after adding adriamycin or nutlin-3, and DMSO as a control, protein was extracted from cell pellets using RIPA buffer with protease inhibitor (Invitrogen). Protein concentration was measured using Bio-Rad protein assay solution. Equal amounts of total protein were separated using SDS-PAGE gels under reducing conditions. The protein was then transferred to a polyvinylidene difluoride (PVDF) membrane (Invitrogen) before being blocked with 5% non-fat milk in TBS-Tween. The membrane was then incubated with primary antibodies against p53, Puma (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) and β-actin (Cell Signaling Technology, Inc., Tokyo, Japan) at a dilution of 1:1,000. The appropriate primary antibodies were followed by horseradish peroxidase (HRP) conjugated secondary antibodies (Amersham Pharmacia Biotech, Piscataway, NJ, USA) at a dilution of 1:10,000. Visualization was achieved using SuperSignal West chemiluminescent solution (Pierce Biotechnology, Inc., Rockford, IL, USA).
Transient transfection of p53-shRNA
To knock down endogenous p53, A549 cells were seeded in 6-well plates at 70–80% confluency. P53-shRNA and its negative control-shRNA were transfected at a final concentration of 100 nM using Lipofectamine RNAiMAX reagent (Invitrogen), and cultured for 48 h using a previously published protocol (15). shRNA suppression efficiency was determined using real-time PCR analysis, and repeated at least three times.
Gemcitabine sensitivity assay with transfection of miR-203 or miR-203 inhibitor
A drug sensitivity assay was performed as described in our previous study (16). HCT116 or A549 cells were seeded in 10-cm dishes at 70% confluency, and cultured for 12 h. miR-203, its inhibitor, and the appropriate controls were then transfected in each dish and cultured overnight. Transfected cells were then seeded in 96-well plates at 4,000 cells/well in triplicates, and incubated for 12 h. Cells were then treating with stepwise, 4-fold serial dilutions of gemcitabine (from 100 μM) and incubated for 96 h. To evaluate cell viability, cells were fixed with 25% glutaraldehyde for 30 min at room temperature, and then stained with 200 μl of 0.05% methylene blue for 20 min. The dye was eluted with 0.33 M HCl while agitating for 20 min. Absorbance was measured using a microplate reader (model 3550; Bio-Rad, Tokyo, Japan) at 598 nm. The 50% inhibitory concentration (IC50) for cell growth was then calculated.
Cell proliferation assay with transfected miR-203 or control
To investigate the miR-203 effect on cell proliferation, growth rates of HCT116 and A549 cells transfected with miR-203 or a control were compared. Growth for both cell lines was carried out using the colorimetric methylene blue assay in 96-well plates at a density of 4,000 cells/well. The first 12 h post-transfection was considered day 0. Mean values were calculated from three different wells in triplicate for four days.
Apoptosis assay
To evaluate whether miR-203 induces caspase-3/7 through the upregulation of Puma, A549 cells were cultured for 12 h in 96-well plates in triplicate, and treated with 50 nM of miR-203, or 50 nM of miR-203 inhibitor or their respective controls. The assay was analyzed using a caspase-3/7 assay kit (Promega, Tokyo, Japan) according to the manufacturer's instructions.
Matrigel cell invasion assay with transfection of miR-203 or miR-203 inhibitor
An invasion assay was performed in 24-well BioCoat Matrigel invasion chambers (Becton-Dickinson, San Diego, CA, USA) following the manufacturer's instructions. A549 cells in 10-cm dishes were cultured for 12 h after being transfected with miR-203, its inhibitor, or their negative controls. Cells were then harvested and seeded in Matrigel-coated (4×104 cells/well) and control-insert wells (4×104 cells/well) before being incubated for 20 h. Cells that penetrated the chamber membranes were considered invasive, and fixed with methanol for 5 min before being stained with crystal violet for 5 min. Cells were observed under a microscope (x20 magnification) and counted in 3 random fields. All assays were performed in triplicates.
Statistical analysis
All results were performed in triplicate and repeated at least two times. Data are shown as the mean ± SD where applicable. Graphpad Prism v5.0 (GraphPad Software, Inc., La Jolla, CA, USA) was used for all statistical analyses. Levels of significance for comparison between cell lines were determined by the Student's t-test distribution. A P-value of <0.05 was considered statistically significant.
Results
miR-203 expression is correlated with Puma expression
Upregulated miR-203 in HCT116 cells increased Puma expression at both the mRNA and protein levels compared to its control. In contrast, miR-203 suppression resulted in decreased Puma expression at the mRNA and protein levels (Fig. 2). The same experiments were repeated in A549 cells, and found to produce the same trend (Fig. 3). These data suggested that miR-203 induced Puma expression. In addition, we measured Bax expression by real-time PCR, but did not find the expression pattern described in other studies (data not shown).
P53 activation was associated with miR-203 and Puma expression in HCT116 and A549 cells. Further studies revealed that activated p53 increased miR-203 and Puma expression in HCT116 cells compared to the control (Fig. 4). Moreover, this finding was validated at both the mRNA and protein levels in A549 cells (Fig. 5A). On the other hand, suppressing p53 significantly reduced miR-203 and Puma expression in A549 cells (Fig. 5B), suggesting that miR-203 expression is influenced by activated p53. To determine whether the miR-203 effect on Puma is facilitated by p53, miR-203 was overexpressed in A549 cells with downregulated p53. This study revealed that Puma levels were increased at both the mRNA and protein levels (Fig. 6). In addition, miR-203 levels were measured following addition of adriamycin or nutlin-3 to p53-knockout cells (A549). The results showed that miR-203 levels did not change compared to the control, but that Puma expression significantly increased (Fig. 6). Overall, these data suggest that miR-203 may induce Puma expression without p53 influence.
miR-203 increases gemcitabine sensitivity while inhibiting cell proliferation in HCT116 and A549 cells
To evaluate the functional role of miR-203 in colon and lung carcinoma cells, pre-miR-203 or its inhibitor was transfected in HCT116 and A549 cells using Lipofectamine. We found that overexpressed miR-203 increased gemcitabine sensitivity and decreased proliferation in both cell lines (Fig. 7). In contrast, down-regulated miR-203 did not show any significant difference in gemcitabine sensitivity or cell proliferation (data not shown). These data suggest that increased miR-203 played an essential role in decreasing chemoresistance.
Overexpressed miR-203 induces apoptosis and decreases cell invasiveness
To examine whether increased Puma expression by miR-203 induces apoptosis, an apoptosis assay was performed. Increased miR-203 resulted in increased apoptosis, while miR-203 inhibition did not affect apoptosis compared to the control (Fig. 8A). Similarly, overexpressed miR-203 decreased the invasive potential of A549 cells, while down-regulated miR-203 had no effect on invasiveness (Fig. 8B).
Discussion
Dysregulated miRNA expression is responsible for the initiation and progression of several types of human cancers. Recent evidence has demonstrated that aberrant miRNA expression affects cell proliferation, invasion, apoptosis, and chemosensitivity (17–19). Among these miRNAs, miR-203 remains an important subject of investigation since its role as a tumor suppressor gene or oncogene remains largely undetermined. Bu and Yang reported that miR-203 is significantly downregulated in malignant melanoma and that it targets versican (20). In addition, Tian et al found that miR-203 levels were significantly lower in squamous cell carcinoma of the larynx compared to the normal surrounding tissue (21). Moreover, Feber et al revealed that miR-203 expression is decreased in esophageal cancer (22), while Wei et al showed similar results in hepatocellular carcinoma (23). In contrast, several studies have found that miR-203 is upregulated in a number of malignancies, including colon cancer, breast cancer, and transitional cell carcinoma of the bladder (24–26). Furthermore, in pancreatic ductal adenocarcinoma, two studies showed that miR-203 is overexpressed and that it is associated with a poorer prognosis (27,28). These two studies also suggested that miR-203 may be a novel prognostic marker for patients with pancreatic cancer. Despite the discrepancies between the miR-203 expression and various malignancies, many studies have considered miR-203 to function as a tumor suppressor gene rather than an oncogene. Additionally, numerous studies have suggested that miR-203 promotes tumorigenesis through its interaction with p53. Likewise, it is well known that miR-203 promotes keratinocyte proliferation and differentiation by targeting p63, a member of the p53 family (29–34). For instance, McKenna et al showed that p53 induces miR-203 in keratinocytes of human foreskin (12). Additionally, p53 has been shown to regulate miR-203 expression in colon cancer cells (35). On the other hand, p53 is a known transcriptional activator of an array of genes that induce apoptosis. One of these genes, named Puma (p53 upregulated modulator of apoptosis), was recently identified by Nakano and Vousden as a ‘BH3-only’ member of the Bcl2 family (11). Furthermore, Hemann et al (36) and Michalak et al (37) reported that the downregulation of Puma effectively suppresses p53-dependent apoptosis. Based on data collected, we hypothesized that miR-203 indirectly regulates Puma expression regardless of p53 activity (Fig. 1). Our data revealed that increased or decreased miR-203 expression correlated positively with Puma expression, and that activated p53 increased both miR-203 and Puma expression. In relation to this finding, we also found that shRNA-mediated inhibition of p53 resulted in decreased expression of both miR-203 and Puma. Collectively, our findings support the idea that miR-203 may be a mediator of the p53-Puma pathway. In addition, we demonstrated that overexpressed miR-203 improved gemcitabine sensitivity; a finding consistent with other data which showed that miR-203 inhibits cell proliferation and invasiveness in prostate carcinoma, and induces apoptosis in transitional cell carcinom (38). Moreover, Feber et al revealed that miR-203 suppresses cell proliferation in esophageal carcinoma (22), while Miao et al showed that miR-203 inhibits cell migration, invasion, and the epithelial-mesenchymal transition (EMT) via caveolin-1 in pancreatic carcinoma (39). Considering these data, our results support the hypothesis that miR-203 acts as a tumor suppressor gene by regulating Puma expression in both colon and lung cancer cells. However, Li et al (40) reported that p53 negatively regulates the miR-203 function when they found that overexpressed miR-203 decreases chemoresistance in p53-mutated colon cancer cells, but has no effect on p53 wild-type cells. In contrast, Li et al supported our findings by showing that overexpressed miR-203 decreases levels of blc-xL (an anti-apoptotic gene), but increases levels of Bax (a pro-apoptotic gene) (40). Clinical data have shown that patients with wild-type p53 colorectal cancer undergoing chemotherapy have significantly better survival than those with mutated p53 (41). The uncertainty of miR-203 function may be due to its targeted activity against numerous molecules involved in a variety of cellular functions. Some of its targets include p63, Akt2, BMI1, and LASP1 which are responsible for cellular proliferation, apoptosis, and chemoresistance (40–46). Even though our results are consistent with previously published data, we acknowledged that our study has some limitations. The most important limitation is the lack of an elucidated pathway through which miR-203 regulates Puma expression. The second limitation is that we do not have a mouse model or clinical data to validate our findings. In conclusion, we have shown that miR-203 expression was affected by p53 activation, and that miR-203 might function as a tumor suppressor gene by regulating Puma expression. Our data also indicated that increased miR-203 was involved in increased gemcitabine sensitivity and decreased cell proliferation in both colon and lung cancer cells. Overall, we believe that our data further support the importance of understanding patient's genetic profiles in order to develop more effective patient-specific therapies, which can lead to improved survival rates and quality of life.